# LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

> **NCT00295958** · PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 26 (actual)

## Conditions studied

- Melanoma (Skin)
- Non-melanomatous Skin Cancer

## Interventions

- **BIOLOGICAL:** LMB-2 immunotoxin
- **BIOLOGICAL:** MART-1 antigen
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** incomplete Freund's adjuvant

## Key facts

- **NCT ID:** NCT00295958
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2006-06
- **Final completion:** 2008-07
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2012-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295958, "LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00295958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*